Cadrenal Therapeutics (CVKD) Profit After Tax (2022 - 2026)

Cadrenal Therapeutics has reported Profit After Tax for 3 years, with the latest figure at -$2.4 million in Q3 2024.

• Quarterly Profit After Tax fell 132.31% year-over-year to -$2.4 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was -$7.6 million (up 37.75% YoY) and the FY2023 annual result came in at -$8.4 million, down 24.47% from the prior year.
• Profit After Tax slipped to -$2.4 million in Q3 2024 per CVKD's latest filing, from -$2.4 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$176648.0 in Q1 2022 and troughed at -$5.2 million in Q1 2023.
• A 3-year average of -$2.0 million and a median of -$1.1 million in 2023 frame the typical range for Profit After Tax.
• The widest YoY moves for Profit After Tax: up 77.16% in 2023, down 2828.75% in 2023.
• Over 3 years, Profit After Tax stood at -$5.0 million in 2022, then surged by 77.16% to -$1.1 million in 2023, then sank by 110.46% to -$2.4 million in 2024.
• According to Business Quant data, Profit After Tax over the past three periods registered -$2.4 million, -$2.4 million, and -$1.7 million for Q3 2024, Q2 2024, and Q1 2024 respectively.